WST - West Pharmaceutical Services Inc Stock Price, Fair Value and News

366.88USD-1.47 (-0.40%)Market Closed

Market Summary

USD366.88-1.47

Market Closed

-0.40%

WST Stock Price

View Fullscreen

WST RSI Chart

WST Valuation

Market Cap

26.8B

Price/Earnings (Trailing)

47.21

Price/Sales (Trailing)

9.17

EV/EBITDA

32.35

Price/Free Cashflow

69.54

WST Price/Sales (Trailing)

WST Profitability

EBT Margin

22.79%

Return on Equity

21.22%

Return on Assets

15.79%

Free Cashflow Yield

1.44%

WST Fundamentals

WST Revenue

Revenue (TTM)

2.9B

Rev. Growth (Yr)

-2.96%

Rev. Growth (Qtr)

-5%

WST Earnings

Earnings (TTM)

568.7M

Earnings Growth (Yr)

-17.64%

Earnings Growth (Qtr)

-15.84%

Breaking Down WST Revenue

52 Week Range

330.16415.73

(Low)(High)

Last 7 days

3.1%

Last 30 days

-6.5%

Last 90 days

-10.8%

Trailing 12 Months

0.4%

How does WST drawdown profile look like?

WST Financial Health

Current Ratio

2.61

Debt/Equity

0.03

Debt/Cashflow

10.39

WST Investor Care

Dividend Yield

0.21%

Dividend/Share (TTM)

0.78

Buy Backs (1Y)

2.22%

Diluted EPS (TTM)

7.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.9B	0	0	0
2023	2.9B	2.9B	2.9B	2.9B
2022	2.9B	2.9B	2.9B	2.9B
2021	2.3B	2.5B	2.7B	2.8B
2020	1.9B	1.9B	2.0B	2.1B
2019	1.7B	1.8B	1.8B	1.8B
2018	1.6B	1.7B	1.7B	1.7B
2017	1.5B	1.5B	1.6B	1.6B
2016	1.4B	1.5B	1.5B	1.5B
2015	1.4B	1.4B	1.4B	1.4B
2014	1.4B	1.4B	1.4B	1.4B
2013	1.3B	1.3B	1.3B	1.4B
2012	1.2B	1.2B	1.2B	1.3B
2011	1.1B	1.2B	1.2B	1.2B
2010	1.1B	1.1B	1.1B	1.1B
2009	0	1.1B	1.1B	1.1B
2008	0	0	0	1.1B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of West Pharmaceutical Services Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 23, 2024	michels douglas a	acquired	-	-	564	-
Apr 23, 2024	pucci paolo	acquired	-	-	564	-
Apr 23, 2024	feehery william f	acquired	-	-	564	-
Apr 23, 2024	hofmann thomas w	acquired	-	-	564	-
Apr 23, 2024	buthman mark a	acquired	-	-	564	-
Apr 23, 2024	keller deborah l	acquired	-	-	564	-
Apr 23, 2024	lockhart stephen h	acquired	-	-	564	-
Apr 23, 2024	friel robert f	acquired	-	-	564	-
Apr 23, 2024	joseph molly	acquired	-	-	564	-
Apr 23, 2024	lai goldman myla	acquired	-	-	564	-

Which funds bought or sold WST recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	GRANDFIELD & DODD, LLC	unchanged	-	87,965	798,543	0.05%
May 06, 2024	Hilltop National Bank	new	-	58,565	58,565	0.02%
May 06, 2024	Davidson Capital Management Inc.	added	0.68	305,893	2,633,060	0.85%
May 06, 2024	Parallel Advisors, LLC	added	6.77	21,818	130,982	-%
May 06, 2024	NEW YORK LIFE INVESTMENT MANAGEMENT LLC	reduced	-3.39	348,742	4,415,730	0.04%
May 06, 2024	Savant Capital, LLC	reduced	-11.65	-1,969	276,207	-%
May 06, 2024	AM Squared Ltd	new	-	39,571	39,571	0.10%
May 06, 2024	Metis Global Partners, LLC	added	1.21	262,985	2,176,400	0.08%
May 06, 2024	DUALITY ADVISERS, LP	sold off	-100	-232,399	-	-%
May 06, 2024	SG Americas Securities, LLC	added	44.4	1,878,000	4,893,000	0.02%

Are Funds Buying or Selling WST?

Are funds buying WST calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own WST

No. of Funds

Unveiling West Pharmaceutical Services Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	12.17%	9,002,632	SC 13G/A
Jan 24, 2024	blackrock inc.	10.5%	7,778,203	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	3.1%	2,301,161	SC 13G/A
Feb 09, 2023	vanguard group inc	12.14%	8,988,409	SC 13G/A
Jan 24, 2023	blackrock inc.	11.0%	8,148,624	SC 13G
Feb 14, 2022	price t rowe associates inc /md/	8.4%	6,241,901	SC 13G/A
Feb 04, 2022	franklin resources inc	3.8%	2,848,869	SC 13G/A
Jan 27, 2022	blackrock inc.	10.9%	8,094,288	SC 13G/A
Jan 25, 2022	blackrock inc.	10.9%	8,094,288	SC 13G/A
Apr 12, 2021	blackrock inc.	10.1%	7,467,809	SC 13G/A

Recent SEC filings of West Pharmaceutical Services Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	8-K	Current Report
Apr 25, 2024	4	Insider Trading
Apr 25, 2024	8-K	Current Report
Apr 25, 2024	4	Insider Trading
Apr 25, 2024	4	Insider Trading
Apr 25, 2024	4	Insider Trading
Apr 25, 2024	4	Insider Trading
Apr 25, 2024	4	Insider Trading
Apr 25, 2024	4	Insider Trading

Peers (Alternatives to West Pharmaceutical Services Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.5B	40.3B	-4.60%	-4.35%	32.81	4.58	-2.84%	-3.08%
BDX	68.5B	19.7B	-3.65%	-5.69%	51.42	3.48	4.82%	-17.56%
ALGN	21.6B	3.9B	-9.77%	-6.38%	46.66	5.51	5.72%	46.72%
BAX	18.4B	14.9B	-15.25%	-20.81%	6.95	1.24	2.98%	207.68%
MID-CAP
ATR	9.9B	3.5B	5.58%	23.16%	31.71	2.8	6.16%	35.06%
HSIC	9.1B	12.5B	-1.81%	-10.76%	23.5	0.73	-0.61%	-18.83%
BIO	8.2B	2.7B	-13.87%	-26.12%	-12.81	3.06	-4.68%	82.43%
XRAY	5.9B	3.9B	-12.53%	-31.61%	-62.76	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	-0.62%	22.51%	-215.76	8.88	30.82%	65.57%
PDCO	2.3B	6.6B	-0.84%	-0.80%	12.05	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.97%	-19.30%	-1.87	0.4	7.94%	-1661.78%
ANIK	420.5M	166.7M	10.85%	9.31%	-5.09	2.52	6.67%	-456.34%
ANGO	245.9M	324.0M	-12.80%	-31.58%	-1.28	0.76	-3.19%	-337.41%
APYX	48.8M	52.3M	-6.00%	-59.48%	-2.61	0.93	17.61%	19.28%
AEMD	3.4M	3.7M	-25.71%	271.43%	-0.27	0.89	5.77%	8.23%

West Pharmaceutical Services Inc News

Latest updates

West Pharmaceutical Services Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-5.0%	695	732	747	754	717	709	687	771	720	731	707	724	671	580	548	527	492	471	456	470	444
Gross Profit	-17.3%	230	278	288	291	271	262	268	322	285	301	288	315	272	211	195	195	167	153	148	158	147
S&GA Expenses	-3.7%	87.00	90.00	89.00	88.00	86.00	86.00	66.00	82.00	83.00	98.00	92.00	93.00	80.00	76.00	76.00	78.00	72.00	69.00	65.00	70.00	69.00
R&D Expenses	-4.3%	18.00	18.00	16.00	17.00	17.00	16.00	14.00	14.00	15.00	14.00	13.00	14.00	12.00	13.00	13.00	11.00	11.00	10.00	9.00	10.00	10.00
EBITDA Margin	-3.0%	0.28*	0.29*	0.27*	0.26*	0.27*	0.28*	0.30*	0.31*	0.31*	0.31*	0.30*	0.28*	0.26*	-	-	-	-	-	-	-	-
Interest Expenses	33.3%	2.00	1.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Income Taxes	-52.5%	16.00	35.00	29.00	35.00	24.00	29.00	20.00	44.00	21.00	34.00	12.00	32.00	29.00	20.00	21.00	16.00	15.00	17.00	11.00	16.00	16.00
Earnings Before Taxes	-24.3%	127	168	187	185	158	129	136	227	188	182	181	211	175	115	98.00	102	87.00	77.00	65.00	80.00	70.00
EBT Margin	-3.7%	0.23*	0.24*	0.23*	0.21*	0.23*	0.24*	0.25*	0.27*	0.26*	0.26*	0.25*	0.24*	0.21*	-	-	-	-	-	-	-	-
Net Income	-15.8%	115	137	161	155	140	103	121	189	174	148	176	187	151	98.00	82.00	91.00	74.00	64.00	56.00	66.00	55.00
Net Income Margin	-3.5%	0.19*	0.20*	0.19*	0.18*	0.19*	0.20*	0.22*	0.23*	0.24*	0.23*	0.23*	0.21*	0.18*	-	-	-	-	-	-	-	-
Free Cashflow	-78.8%	28.00	130	134	94.00	56.00	136	111	107	85.00	84.00	125	88.00	34.00	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-5.9%	3,602	3,830	3,755	3,670	3,724	3,617	3,317	3,362	3,295	3,314	3,143	2,934	2,740	2,794	2,583	2,392	2,247	2,341	2,174	2,123	2,036
Current Assets	-12.6%	1,693	1,936	1,972	1,874	1,937	1,920	1,734	1,771	1,691	1,742	1,598	1,477	1,327	1,374	1,238	1,111	978	1,059	1,004	944	868
Cash Equivalents	-29.5%	602	854	899	796	886	894	729	719	668	763	688	576	484	616	519	446	335	439	396	327	266
Inventory	-1.1%	430	435	432	449	447	415	413	412	417	378	354	345	310	321	295	275	251	236	230	232	226
Net PPE	2.5%	1,449	1,413	1,312	1,261	1,215	1,158	1,069	1,077	1,066	1,058	1,007	973	931	943	883	840	828	839	812	823	815
Goodwill	-0.8%	108	109	107	108	108	107	104	107	109	110	109	110	110	111	109	108	107	108	107	108	105
Liabilities	-2.8%	922	949	887	923	947	932	846	937	969	978	940	901	911	939	864	786	756	768	686	678	667
Current Liabilities	-3.5%	648	672	534	512	535	519	457	565	585	594	559	473	483	503	448	375	344	342	335	313	301
Long Term Debt	0%	73.00	73.00	152	206	206	207	207	208	208	209	210	252	252	253	253	254	254	255	195	196	196
LT Debt, Non Current	0%	73.00	73.00	152	206	206	207	207	208	208	209	210	252	252	253	253	254	254	255	195	196	196
Shareholder's Equity	-7.0%	2,681	2,881	2,868	2,747	2,776	2,685	2,471	2,424	2,326	2,335	2,202	2,033	1,829	1,855	1,719	1,606	1,490	1,573	1,488	1,445	1,370
Retained Earnings	2.9%	3,624	3,523	3,416	3,255	3,114	2,988	2,913	2,793	2,617	2,457	2,336	2,160	1,985	1,847	1,773	1,703	1,612	1,549	1,497	1,453	1,398
Additional Paid-In Capital	-54.1%	55.00	120	123	158	181	232	231	225	220	249	251	248	247	267	268	263	268	273	269	273	279
Accumulated Depreciation	1.4%	1,343	1,325	1,296	1,282	1,264	1,228	1,164	1,169	1,171	1,158	1,140	1,125	1,098	1,092	1,056	1,018	989	981	968	964	945
Shares Outstanding	-0.7%	73.00	74.00	74.00	74.00	75.00	74.00	74.00	74.00	74.00	74.00	74.00	74.00	74.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	28,200	-	-	-	22,300	-	-	-	26,500	-	-	-	16,742	-	-	-	9,218	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-50.6%	118,200	239,100	230,100	169,200	138,100	230,800	168,900	173,100	151,200	160,800	190,100	144,400	88,700	148,700	118,600	148,100	57,100	106,400	108,100	105,100	47,600
Share Based Compensation	257.1%	5,000	1,400	5,900	7,500	8,500	6,700	6,000	5,500	5,500	9,950	11,400	10,300	5,900	6,350	10,000	12,300	5,400	5,600	5,400	7,200	6,200
Cashflow From Investing	16.7%	-90,600	-108,800	-95,700	-82,100	-82,100	-94,800	-59,100	-66,000	-68,300	-77,400	-65,300	-55,900	-54,500	-57,600	-49,100	-40,900	-31,900	-120,600	-31,600	-47,100	-28,700
Cashflow From Financing	-43.0%	-271,000	-189,500	-22,300	-176,800	-71,000	-9,500	-75,200	-36,200	-172,700	-6,200	-5,800	300	-156,400	-8,700	-7,200	-900	-120,300	51,000	-400	3,100	-90,500
Dividend Payments	-0.7%	14,700	14,800	14,000	14,100	14,100	14,100	13,500	13,100	13,400	13,300	12,600	12,600	12,600	12,600	11,900	11,800	11,800	11,800	11,100	11,100	11,100
Buy Backs	50.8%	267,000	177,000	27,800	173,400	60,100	-100	27,200	28,600	147,100	-	-	-	137,100	-	-	-	115,500	-	-	-	83,100

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

WST Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net sales	$ 695.4	$ 716.6
Cost of goods and services sold	465.2	445.3
Gross profit	230.2	271.3
Research and development	17.6	17.1
Selling, general and administrative expenses	86.7	86.0
Other expense (income) (Note 14)	3.1	12.9
Operating profit	122.8	155.3
Interest expense	1.6	2.2
Interest income	(6.2)	(4.8)
Income before income taxes and equity in net income of affiliated companies	127.4	157.9
Income tax expense	16.4	23.6
Equity in net income of affiliated companies	(4.3)	(5.7)
Net income	$ 115.3	$ 140.0
Net income per share:
Basic (in dollars per share)	$ 1.57	$ 1.88
Diluted (in dollars per share)	$ 1.55	$ 1.85
Weighted average shares outstanding:
Basic (in shares)	73.5	74.5
Diluted (in shares)	74.3	75.7

WST Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 601.8	$ 853.9
Accounts receivable, net	524.0	512.0
Inventories	429.9	434.7
Other current assets	137.2	135.8
Total current assets	1,692.9	1,936.4
Property, plant and equipment	2,791.3	2,738.0
Less: accumulated depreciation and amortization	1,342.7	1,324.7
Property, plant and equipment, net	1,448.6	1,413.3
Operating lease right-of-use assets	96.8	99.2
Investments in affiliated companies	202.5	210.0
Goodwill	107.6	108.5
Intangible assets, net	13.9	15.1
Deferred income taxes	21.0	25.7
Other noncurrent assets	19.0	21.3
Total Assets	3,602.3	3,829.5
Current liabilities:
Notes payable and other current debt	133.4	134.0
Accounts payable	240.1	242.4
Accrued salaries, wages and benefits	66.5	105.9
Income taxes payable	16.8	16.6
Operating lease liabilities	18.0	17.7
Other current liabilities	173.6	155.2
Total current liabilities	648.4	671.8
Long-term debt	72.8	72.8
Deferred income taxes	12.7	12.7
Pension and other postretirement benefits	28.9	29.6
Long-term operating lease liabilities	82.4	84.5
Deferred compensation benefits	18.6	18.6
Other long-term liabilities	57.9	58.5
Total Liabilities	921.7	948.5
Commitments and contingencies (Note 16)
Equity:
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding	0.0	0.0
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million as of March 31, 2024 and December 31, 2023, respectively; shares outstanding: 73.0 million and 73.5 million as of March 31, 2024 and December 31, 2023, respectively	18.8	18.8
Capital in excess of par value	55.2	120.2
Retained earnings	3,624.1	3,523.4
Accumulated other comprehensive loss	(192.3)	(143.8)
Treasury stock, at cost (2.3 million and 1.8 million shares)	(825.2)	(637.6)
Total Equity	2,680.6	2,881.0
Total Liabilities and Equity	$ 3,602.3	$ 3,829.5

About West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. The company was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

CEO	Mr. Eric M. Green
WEBSITE	westpharma.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	10700

West Pharmaceutical Services Inc Frequently Asked Questions

What is the ticker symbol for West Pharmaceutical Services Inc? What does WST stand for in stocks?

WST is the stock ticker symbol of West Pharmaceutical Services Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of West Pharmaceutical Services Inc (WST)?

As of Tue May 07 2024, market cap of West Pharmaceutical Services Inc is 26.85 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of WST stock?

You can check WST's fair value in chart for subscribers.

What is the fair value of WST stock?

You can check WST's fair value in chart for subscribers. The fair value of West Pharmaceutical Services Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of West Pharmaceutical Services Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for WST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is West Pharmaceutical Services Inc a good stock to buy?

The fair value guage provides a quick view whether WST is over valued or under valued. Whether West Pharmaceutical Services Inc is cheap or expensive depends on the assumptions which impact West Pharmaceutical Services Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for WST.

What is West Pharmaceutical Services Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, WST's PE ratio (Price to Earnings) is 47.21 and Price to Sales (PS) ratio is 9.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. WST PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on West Pharmaceutical Services Inc's stock?

In the past 10 years, West Pharmaceutical Services Inc has provided 0.245 (multiply by 100 for percentage) rate of return.